A role for dihydrotestosterone treatment in older men?

Asian Journal of Andrology

Volumn 13, Issue 2, 2011, Pages 199-200

  Roth, Mara Y ^a   Page, Stephanie T ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; PLACEBO;

ABSENCE OF SIDE EFFECTS; AGED; AGING; ANDROGEN DEFICIENCY; BODY COMPOSITION; BONE DENSITY; BONE MINERAL; DRUG MEGADOSE; HUMAN; HYPOGONADISM; LIPID BLOOD LEVEL; MALE; NOTE; QUALITY OF LIFE; QUESTIONNAIRE; STEROID METABOLISM; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

AGED; BONE DENSITY; DIHYDROTESTOSTERONE; ESTRADIOL; HUMANS; MALE; PROSTATE; TESTOSTERONE;

EID: 79952414049     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.173     Document Type: Note

References (11)

1. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589-98. (Pubitemid 34158223)
2. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-59.
3. Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L et al. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease. Ann Intern Med 2010; 153:621-32.
4. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 2002; 99: 13589-94. (Pubitemid 35221316)
5. Mc Connell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63. (Pubitemid 28114643)
6. Ly LP, Jimenez M, Zhuang TN,Celermajer DS, Conway AJ et al. A double-blind, placebo-controlled, randomizedtrial oftransdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001; 86: 4078-88. (Pubitemid 32848516)
7. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double-blind study. J Clin Endocrinol Metab 2002; 87: 1467-72. (Pubitemid 34615223)
8. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD et al. Exogenous testosterone or testosterone with finasterideincreasebonemineraldensityinoldermen with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503-10. (Pubitemid 38269849)
9. Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K. Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 2003; 88: 2784-93. (Pubitemid 36724456)
10. Wang C, Iranmanesh A, Berman N, Mc Donald V, Steiner B et al. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men\a clinical research center study. J Clin Endocrinol Metab 1998; 83: 2749-57. (Pubitemid 28493771)
11. Bagatell CJ, Knopp RH, Rivier JE, Bremner WJ. Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men. J Clin Endocrinol Metab 1994; 78: 855-61. (Pubitemid 24118078)